Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.

Author's Avatar
May 05, 2023

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of Lexiscan® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).